uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1764 | Q34 | What are the names of the genes that are targeted by the drug Dexlansoprazole in the treatment of duodenal ulcer? | In the context of duodenal ulcer, the drug Dexlansoprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duodenal ulcer%" OR LOWER(efo_term) LIKE "%duodenal ulcer%") AND (LOWER(drugName) LIKE "%dexlansoprazole%" OR LOWER(tradeNames_list) LIKE "%dexlansoprazole%" OR LOWER(syns_list) LIKE "%dexlansoprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1098464', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098488', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098496', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098504', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098520', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098528', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098536', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098552', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098560', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098568', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098576', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098592', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098600', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098608', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098616', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098624', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098632', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098640', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098648', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098656', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098664', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098680', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098688', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098696', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098704', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098712', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098728', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098736', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098744', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098752', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098760', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098768', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098776', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098784', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098792', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098800', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098808', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098816', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098824', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098832', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098840', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098848', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098856', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098864', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098872', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098880', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098888', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098896', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098904', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098912', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098920', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098936', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098944', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098952', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098960', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098968', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098976', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098992', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099000', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099008', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099016', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099024', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099032', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099040', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099048', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099056', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099064', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099072', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099080', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099088', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099096', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099104', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099112', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099120', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099128', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099136', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099144', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099152', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099160', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099168', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099176', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099184', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099192', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099200', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099208', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099216', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098928', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098672', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098544', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098480', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098448', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098432', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098424', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098984', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098720', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098584', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098512', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098472', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098456', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098440', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.600 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of epilepsy with generalized tonic-clonic seizures? | In the context of epilepsy with generalized tonic-clonic seizures, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy with generalized tonic-clonic seizures%" OR LOWER(efo_term) LIKE "%epilepsy with generalized tonic-clonic seizures%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653154', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653247', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653278', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653309', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653371', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653402', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653433', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653495', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653526', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653557', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653588', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653650', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653681', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653712', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653743', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653774', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653805', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653836', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653867', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653898', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653929', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653991', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654022', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654053', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654084', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654115', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654177', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654208', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654239', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654270', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654301', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654332', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654363', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654394', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654425', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654456', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654487', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654518', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654549', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654580', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654611', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654642', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654673', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654704', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654735', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654766', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654797', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654828', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654859', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654890', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654921', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654983', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655014', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655045', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655076', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655107', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655138', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655200', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655231', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655262', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655293', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655324', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655355', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655386', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655417', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655448', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655479', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655510', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655541', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655572', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655603', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655634', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655665', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655696', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655727', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655758', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655789', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655820', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655851', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655882', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655913', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655944', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655975', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656006', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656037', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656068', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654952', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653960', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653464', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653216', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653092', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653030', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652999', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655169', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654146', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653619', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653340', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653185', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653123', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653061', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.62 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of Nausea and vomiting? | In the context of Nausea and vomiting, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea and vomiting%" OR LOWER(efo_term) LIKE "%nausea and vomiting%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199679', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199692', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199695', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199700', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199687', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199671', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199663', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199660', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199703', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199684', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199676', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199668', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1307 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972648', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972716', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972580', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972512', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972478', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972682', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972614', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972546', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.878 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of Myalgia? | In the context of Myalgia, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837124', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837214', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837244', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837274', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837334', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837364', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837394', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837454', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837484', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837514', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837544', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837604', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837634', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837664', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837694', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837724', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837754', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837784', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837814', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837844', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837874', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837934', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837964', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837994', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838024', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837904', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837184', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837064', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837004', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836974', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837424', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837574', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837304', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837154', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837094', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837034', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1476 | Q34 | What are the names of the genes that are targeted by the drug Eltrombopag Olamine in the treatment of chronic hepatitis C virus infection? | In the context of chronic hepatitis C virus infection, the drug Eltrombopag Olamine targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic hepatitis c virus infection%" OR LOWER(efo_term) LIKE "%chronic hepatitis c virus infection%") AND (LOWER(drugName) LIKE "%eltrombopag olamine%" OR LOWER(tradeNames_list) LIKE "%eltrombopag olamine%" OR LOWER(syns_list) LIKE "%eltrombopag olamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055973', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055988', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055993', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055998', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056008', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056013', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056018', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056028', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056033', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056038', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056043', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056053', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056058', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056063', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056068', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056073', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056078', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056083', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056088', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056093', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056098', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056108', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056113', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056118', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056123', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056128', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056138', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056143', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056148', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056153', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056158', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056163', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056168', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056173', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056178', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056183', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056188', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056193', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056198', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056203', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056208', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056213', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056218', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056223', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056228', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056233', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056238', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056243', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056248', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056253', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056258', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056268', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056273', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056278', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056283', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056288', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056293', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056303', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056308', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056313', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056318', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056323', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056328', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056333', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056338', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056343', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056348', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056353', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056358', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056363', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056368', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056373', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056378', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056383', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056388', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056393', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056398', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056403', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056408', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056413', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056418', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056423', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056428', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056433', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056438', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056443', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056263', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056103', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056023', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055983', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055963', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055953', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055948', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056298', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056133', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056048', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1056003', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055978', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055968', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055958', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'syns_list': "['Eltrombopag (as olamine)', 'Eltrombopag compd with 2-aminoethanol (1:2)Eltrombopag olamine', 'SB-497115-GR']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1861 | Q34 | What are the names of the genes that are targeted by the drug Pitavastatin Magnesium in the treatment of Abnormal circulating lipid concentration? | In the context of Abnormal circulating lipid concentration, the drug Pitavastatin Magnesium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%abnormal circulating lipid concentration%" OR LOWER(efo_term) LIKE "%abnormal circulating lipid concentration%") AND (LOWER(drugName) LIKE "%pitavastatin magnesium%" OR LOWER(tradeNames_list) LIKE "%pitavastatin magnesium%" OR LOWER(syns_list) LIKE "%pitavastatin magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104303', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104305', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104307', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.280 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of asthma? | In the context of asthma, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225663', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225690', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225699', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225708', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225726', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225735', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225744', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225762', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225771', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225780', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225789', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225807', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225816', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225825', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225834', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225843', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225852', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225861', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225870', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225879', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225888', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225906', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225915', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225924', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225933', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225942', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225960', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225969', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225978', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225987', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225996', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226005', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226014', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226023', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226032', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226041', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226050', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226059', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226068', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226077', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226086', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226095', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226104', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225897', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225753', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225681', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225645', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225627', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225618', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225951', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225798', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225717', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225672', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225654', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225636', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.37 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of Agitation? | In the context of Agitation, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%agitation%" OR LOWER(efo_term) LIKE "%agitation%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_159196', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159280', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159308', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159336', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159392', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159420', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159448', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159504', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159532', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159560', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159588', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159644', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159672', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159700', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159728', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159756', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159784', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159812', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159840', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159868', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159896', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159952', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159980', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160008', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160036', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160064', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160120', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160148', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160176', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160204', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160232', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160260', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160288', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160316', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160344', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160372', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160400', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160428', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160456', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160484', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160512', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160540', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160568', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160596', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160624', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160652', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160680', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160708', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160736', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160764', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160792', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160848', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160876', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160904', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160932', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160960', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160988', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161044', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161072', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161100', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161128', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161156', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161184', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161212', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161240', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161268', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161296', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161324', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161352', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161380', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161408', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161436', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161464', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161492', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161520', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161548', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161576', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161604', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161632', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161660', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161688', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161716', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161744', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161772', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161800', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161828', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160820', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159924', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159476', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159252', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159140', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159084', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159056', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161016', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160092', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159616', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159364', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159224', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159168', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159112', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychomotor Agitation', 'efo_term': 'Agitation', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1502 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of polyarticular arthritis? | In the context of polyarticular arthritis, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polyarticular arthritis%" OR LOWER(efo_term) LIKE "%polyarticular arthritis%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057603', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058086', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058247', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058408', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058730', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058891', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059052', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059374', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059535', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059696', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059857', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060179', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060340', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060501', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060662', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060823', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060984', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061145', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061306', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061467', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061628', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061950', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062111', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062272', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062433', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062594', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062916', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063077', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063238', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063399', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063560', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063721', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063882', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064043', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064204', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064365', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064526', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064687', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064848', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065009', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065170', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065331', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065492', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065653', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065814', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065975', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066136', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066297', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066458', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066619', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066780', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067102', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067263', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067424', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067585', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067746', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067907', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068229', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068390', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068551', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068712', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068873', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069034', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069195', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069356', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069517', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069678', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069839', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070000', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070161', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070322', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070483', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070644', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070805', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070966', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071127', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071288', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071449', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071610', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071771', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071932', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072093', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072254', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072415', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066941', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061789', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059213', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057925', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057281', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056959', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056798', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068068', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062755', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060018', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058569', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057764', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057442', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057120', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'polyarticular arthritis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.667 | Q34 | What are the names of the genes that are targeted by the drug Roflumilast in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Roflumilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%roflumilast%" OR LOWER(tradeNames_list) LIKE "%roflumilast%" OR LOWER(syns_list) LIKE "%roflumilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695491', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695554', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695575', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695596', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695638', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695659', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695680', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695722', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695743', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695764', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695785', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695827', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695848', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695869', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695890', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695911', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695932', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695953', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695974', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695995', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696016', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696058', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696079', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696100', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696121', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696142', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696184', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696205', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696226', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696247', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696268', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696289', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696310', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696331', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696352', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696373', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696394', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696415', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696436', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696457', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696478', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696499', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696520', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696541', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696037', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695701', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695533', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695449', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695407', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695386', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696163', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695806', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695617', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695512', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695470', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695428', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1790 | Q34 | What are the names of the genes that are targeted by the drug Dantrolene Sodium in the treatment of stroke? | In the context of stroke, the drug Dantrolene Sodium targets the gene ryanodine receptor 3 and ryanodine receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%dantrolene sodium%" OR LOWER(tradeNames_list) LIKE "%dantrolene sodium%" OR LOWER(syns_list) LIKE "%dantrolene sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100247', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100256', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100220', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100274', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100301', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100238', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100292', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100283', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100229', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100265', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100226', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100262', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100271', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100280', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100217', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100235', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100253', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100289', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100298', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100244', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Heat Stroke', 'efo_term': 'Heat Stroke', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1429 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043733', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043775', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043789', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043803', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043831', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043845', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043859', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043887', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043901', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043915', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043929', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043957', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043971', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043985', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043873', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043761', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043705', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043677', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043663', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043943', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043817', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043747', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043719', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043691', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.984 | Q34 | What are the names of the genes that are targeted by the drug Abemaciclib in the treatment of breast cancer? | In the context of breast cancer, the drug Abemaciclib targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%abemaciclib%" OR LOWER(tradeNames_list) LIKE "%abemaciclib%" OR LOWER(syns_list) LIKE "%abemaciclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_849250', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849352', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849199', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850168', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850372', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849301', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850270', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850831', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849658', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850576', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849148', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850627', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849556', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849607', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851188', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850321', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849403', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849964', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849097', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850474', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850984', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850729', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850882', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850117', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850066', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850780', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850015', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849760', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849505', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851086', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849913', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850219', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849862', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850933', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851137', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850678', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849709', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851239', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850423', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849454', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849811', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851290', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851035', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850525', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850203', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850254', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850662', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849387', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849693', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850305', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850356', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849744', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850407', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850458', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849132', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849234', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849795', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850509', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850560', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849642', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849081', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849285', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849489', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849897', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850764', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849948', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850815', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849438', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849540', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849999', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850917', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850866', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850968', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850050', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851019', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851070', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850713', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849336', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849591', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850101', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851121', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849183', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851172', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850152', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851223', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851274', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850611', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849846', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1557 | Q34 | What are the names of the genes that are targeted by the drug Macitentan in the treatment of idiopathic and/or familial pulmonary arterial hypertension? | In the context of idiopathic and/or familial pulmonary arterial hypertension, the drug Macitentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%macitentan%" OR LOWER(tradeNames_list) LIKE "%macitentan%" OR LOWER(syns_list) LIKE "%macitentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1083999', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084029', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084039', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084019', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083959', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083949', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083979', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084009', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083989', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083969', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.743 | Q34 | What are the names of the genes that are targeted by the drug Buprenorphine in the treatment of Chronic pain? | In the context of Chronic pain, the drug Buprenorphine targets the gene opioid receptor mu 1 and opioid receptor kappa 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%buprenorphine%" OR LOWER(tradeNames_list) LIKE "%buprenorphine%" OR LOWER(syns_list) LIKE "%buprenorphine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764193', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764277', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764305', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764333', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764389', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764417', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764445', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764501', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764529', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764557', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764585', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764641', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764669', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764697', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764725', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764753', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764781', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764809', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764837', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764865', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764893', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764949', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764977', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765005', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765033', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765061', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765117', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765145', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765173', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765201', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765229', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765257', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765285', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765313', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765341', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765369', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765397', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765425', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765453', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765481', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765509', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765537', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765565', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765593', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765621', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765649', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765677', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765705', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765733', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765761', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765789', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765845', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765873', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765901', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765929', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765957', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765985', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766041', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766069', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766097', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766125', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766153', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766181', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766209', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766237', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766265', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766293', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766321', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766349', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766377', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766405', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766433', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766461', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766489', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766517', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766545', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765817', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764921', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764473', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764249', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764137', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764081', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764053', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766013', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765089', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764613', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764361', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764221', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764165', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764109', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.193 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of keratitis? | In the context of keratitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%keratitis%" OR LOWER(efo_term) LIKE "%keratitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218699', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219323', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219531', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219739', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220155', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220363', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220571', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220779', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219115', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218283', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217867', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217659', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219947', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218907', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218491', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218075', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.926 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Headache? | In the context of Headache, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%headache%" OR LOWER(efo_term) LIKE "%headache%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_839998', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841104', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840946', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840393', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840472', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839761', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841578', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840867', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840551', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841183', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839840', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840077', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841025', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840235', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840709', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840156', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841499', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841657', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841420', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841262', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840314', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840630', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839919', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841736', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841341', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840788', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Headache', 'efo_term': 'Headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840738', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839948', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840817', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839711', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840027', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840343', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840975', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840264', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840422', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841133', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841212', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840106', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840501', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841291', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841370', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841054', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840580', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841449', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841528', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839790', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839869', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840185', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840659', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841607', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841686', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840896', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Tension-Type Headache', 'efo_term': 'Tension-type headache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.460 | Q34 | What are the names of the genes that are targeted by the drug Phenylephrine Hydrochloride in the treatment of common cold? | In the context of common cold, the drug Phenylephrine Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%phenylephrine hydrochloride%" OR LOWER(syns_list) LIKE "%phenylephrine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416702', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416630', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416612', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416666', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416684', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_416648', 'drugName': 'Phenylephrine Hydrochloride', 'tradeNames_list': "['Afrin 4 hour nasal spray', 'Biomydrin', 'Biorphen', 'Fenilfar', 'FenoxMydfrin', 'Nazex', 'Neo-synephrine', 'Neosynephrine', 'NostrilNurofen sinus pain relief', 'Phenylephrine hydrochloride', 'PrefrinVazculep']", 'syns_list': "['Metaoxedrine chloride', 'NSC-757273', 'Phenylephrine HClPhenylephrine hydrochloride']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.680 | Q34 | What are the names of the genes that are targeted by the drug Erdafitinib in the treatment of neoplasm? | In the context of neoplasm, the drug Erdafitinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_list) LIKE "%erdafitinib%" OR LOWER(syns_list) LIKE "%erdafitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707253', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707209', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707223', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707159', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707127', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707334', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707109', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707111', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707284', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707097', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707301', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707238', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707124', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707382', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707348', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707174', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707177', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707332', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707094', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707189', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707191', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707141', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707142', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707143', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707287', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707113', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707221', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707364', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707156', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707317', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707158', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707316', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707241', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707303', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707305', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707385', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707093', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707381', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707173', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707383', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707175', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707319', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707129', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707397', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707333', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707335', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707188', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707396', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707190', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707337', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707193', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707110', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707271', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707172', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707204', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707205', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707206', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707350', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707145', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707273', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707126', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707349', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707220', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707285', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707222', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707369', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707225', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707270', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707268', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707353', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707300', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707236', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707237', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707367', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707239', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707269', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707161', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707366', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707302', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707365', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707252', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707398', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707254', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707255', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707257', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707401', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707399', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707380', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707351', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707318', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707289', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707140', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707095', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707207', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707286', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707157', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707321', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707108', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707092', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707125', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.765 | Q34 | What are the names of the genes that are targeted by the drug Fentanyl in the treatment of Chronic pain? | In the context of Chronic pain, the drug Fentanyl targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%fentanyl%" OR LOWER(tradeNames_list) LIKE "%fentanyl%" OR LOWER(syns_list) LIKE "%fentanyl%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_787960', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787048', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786516', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785984', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786288', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789138', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786592', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786744', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788378', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785756', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788568', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787656', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786060', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788948', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786212', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788986', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786364', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789214', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788074', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786136', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786668', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786820', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788226', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786972', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788416', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785718', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785794', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788644', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785870', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787504', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785946', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788682', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786022', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787808', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786098', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789100', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786174', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788910', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786250', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789062', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786326', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786896', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787352', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789252', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786478', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789176', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786554', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789328', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786630', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789290', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786706', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786782', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788150', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786858', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788302', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786934', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788264', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788492', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787086', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787124', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787162', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788454', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787238', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787276', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787314', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788796', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787390', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787428', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787466', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788606', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787542', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787580', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787618', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788758', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787694', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787732', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787770', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788720', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787846', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787884', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787922', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788036', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787998', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788834', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788530', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788340', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788188', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788112', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786402', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789024', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787010', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787200', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785908', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788872', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786440', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785832', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785603', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785449', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785614', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785625', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1791 | Q34 | What are the names of the genes that are targeted by the drug Dantrolene Sodium in the treatment of cerebral palsy? | In the context of cerebral palsy, the drug Dantrolene Sodium targets the gene ryanodine receptor 3 and ryanodine receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cerebral palsy%" OR LOWER(efo_term) LIKE "%cerebral palsy%") AND (LOWER(drugName) LIKE "%dantrolene sodium%" OR LOWER(tradeNames_list) LIKE "%dantrolene sodium%" OR LOWER(syns_list) LIKE "%dantrolene sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100266', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100293', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100302', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100284', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100230', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100221', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100248', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100275', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100257', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100239', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1588 | Q34 | What are the names of the genes that are targeted by the drug Temsirolimus in the treatment of cancer? | In the context of cancer, the drug Temsirolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%temsirolimus%" OR LOWER(tradeNames_list) LIKE "%temsirolimus%" OR LOWER(syns_list) LIKE "%temsirolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091012', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091087', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091387', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091312', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091462', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091162', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091237', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090712', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090787', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090862', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090937', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090861', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091011', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090711', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090936', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091461', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091236', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091161', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091311', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091086', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091386', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090786', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090924', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090994', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090996', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090776', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091375', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090926', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090995', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091372', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091294', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091371', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090699', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090771', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090925', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091369', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091370', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090775', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091001', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090921', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090923', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090998', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091226', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090922', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091076', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091150', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090774', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091376', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091074', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090851', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090770', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091374', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091373', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090919', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090850', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090849', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090769', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091146', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091147', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091144', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091298', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090694', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090700', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091296', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090772', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091299', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091295', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091072', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091073', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091075', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091219', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090846', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091071', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091070', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090773', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090701', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091145', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091297', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091148', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091149', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091069', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091223', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091220', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090845', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090698', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091225', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090920', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091000', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090999', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090844', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091300', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091221', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090847', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091222', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091224', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090848', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091151', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091301', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090695', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090696', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.733 | Q34 | What are the names of the genes that are targeted by the drug Eluxadoline in the treatment of irritable bowel syndrome? | In the context of irritable bowel syndrome, the drug Eluxadoline targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%irritable bowel syndrome%" OR LOWER(efo_term) LIKE "%irritable bowel syndrome%") AND (LOWER(drugName) LIKE "%eluxadoline%" OR LOWER(tradeNames_list) LIKE "%eluxadoline%" OR LOWER(syns_list) LIKE "%eluxadoline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763315', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763318', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763319', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763320', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763322', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763323', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763324', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763326', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763327', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763328', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763329', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763331', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763332', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763333', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763334', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763335', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763336', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763337', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763338', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763339', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763340', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763342', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763343', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763344', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763345', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763346', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763348', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763349', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763341', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763325', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763317', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763313', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763311', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763310', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763347', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763330', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763321', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763316', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763314', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763312', 'drugName': 'Eluxadoline', 'tradeNames_list': "['Truberzi', 'Viberzi']", 'syns_list': "['Eluxadoline', 'JNJ-27018966']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Irritable Bowel Syndrome', 'efo_term': 'irritable bowel syndrome', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.415 | Q34 | What are the names of the genes that are targeted by the drug Fenofibric Acid in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Fenofibric Acid targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%fenofibric acid%" OR LOWER(tradeNames_list) LIKE "%fenofibric acid%" OR LOWER(syns_list) LIKE "%fenofibric acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243842', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243818', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243866', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243872', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243836', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243890', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243896', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243854', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243860', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243902', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243830', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243878', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243884', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243812', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243848', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243824', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243904', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243909', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1106 | Q34 | What are the names of the genes that are targeted by the drug Darolutamide in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Darolutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_list) LIKE "%darolutamide%" OR LOWER(syns_list) LIKE "%darolutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924425', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924439', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924411', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924397', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924390', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924432', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924418', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924404', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.831 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of common cold? | In the context of common cold, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829263', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829578', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829683', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829788', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829998', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830103', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830208', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830418', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830523', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830628', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830733', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830943', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831048', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831153', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831258', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831363', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831468', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831573', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831678', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831783', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831888', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832098', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832203', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832308', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832413', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832518', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832728', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832833', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831993', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830313', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829473', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829053', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828843', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828738', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832623', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830838', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829893', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829368', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829158', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828948', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1483 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057584', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058067', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058228', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058389', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058711', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058872', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059033', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059355', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059516', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059677', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059838', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060160', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060321', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060482', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060643', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060804', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060965', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061126', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061287', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061448', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061609', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061931', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062092', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062253', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062414', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062575', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062897', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063058', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063219', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063380', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063541', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063702', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063863', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064024', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064185', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064346', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064507', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064668', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064829', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064990', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065151', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065312', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065473', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065634', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065795', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065956', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066117', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066278', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066439', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066600', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066761', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067083', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067244', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067405', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067566', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067727', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067888', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068210', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068371', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068532', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068693', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068854', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069015', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069176', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069337', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069498', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069659', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069820', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069981', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070142', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070303', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070464', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070625', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070786', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070947', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071108', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071269', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071430', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071591', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071752', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071913', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072074', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072235', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072396', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066922', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061770', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059194', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057906', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057262', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056940', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056779', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068049', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062736', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059999', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058550', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057745', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057423', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057101', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.621 | Q34 | What are the names of the genes that are targeted by the drug Nintedanib in the treatment of neoplasm? | In the context of neoplasm, the drug Nintedanib targets the gene kinase insert domain receptor, fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, platelet derived growth factor receptor alpha and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%nintedanib%" OR LOWER(tradeNames_list) LIKE "%nintedanib%" OR LOWER(syns_list) LIKE "%nintedanib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_680384', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_682781', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_682640', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_679491', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_679867', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_682405', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678786', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679961', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_680666', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_680854', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_681277', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_681606', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_681794', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682499', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_681841', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682546', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_682452', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_679209', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_682311', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_682170', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_680102', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678974', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680431', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680478', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680807', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_679162', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_680995', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_681559', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_678692', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_681371', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_681418', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_681747', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_679538', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_679397', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_681888', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_681982', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_679773', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_680337', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_679914', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_682687', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_679726', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_679585', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_682217', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678833', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680008', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_682264', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_682875', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_681935', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_680149', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_679632', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_682734', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_679115', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680290', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680243', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680572', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_679021', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680525', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_681183', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_679256', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_680760', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_680713', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_681136', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_680901', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_681089', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_681042', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682076', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_678739', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679303', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_678880', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_681512', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_679350', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_681465', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682593', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_682029', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_679679', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_681700', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_681653', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682123', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_681230', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_680619', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_679444', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_680196', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678927', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_679820', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_682828', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_679068', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680948', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_681324', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682358', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_680055', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_680006', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_680050', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_680191', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_678781', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680053', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_678784', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_680097', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680100', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680144', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_680147', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'syns_list': "['BIBF 1120', 'BIBF-1120', 'BIBF1120', 'Bibf-1120', 'Intedanib', 'Nintedanib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.116 | Q34 | What are the names of the genes that are targeted by the drug Escitalopram Oxalate in the treatment of unipolar depression? | In the context of unipolar depression, the drug Escitalopram Oxalate targets the gene solute carrier family 6 member 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%escitalopram oxalate%" OR LOWER(tradeNames_list) LIKE "%escitalopram oxalate%" OR LOWER(syns_list) LIKE "%escitalopram oxalate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206519', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206536', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206537', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206545', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206554', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206555', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206563', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206572', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206573', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206581', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206582', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206591', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206599', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206600', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206564', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206528', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206510', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206501', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206500', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206590', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206546', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206527', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206518', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206509', 'drugName': 'Escitalopram Oxalate', 'tradeNames_list': "['Escitalopram oxalate', 'Lexapro']", 'syns_list': "['Citalopram oxalate, (s)-', 'Escitalopram (as oxalate)Escitalopram oxalate', 'LU 26-054-0', 'LU-26-054-0', 'LU-26-054-ONSC-758934']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.420 | Q34 | What are the names of the genes that are targeted by the drug Fenofibrate in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_list) LIKE "%fenofibrate%" OR LOWER(syns_list) LIKE "%fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244026', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244113', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244142', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244171', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244229', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244258', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244287', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244345', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244374', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244403', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244432', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244084', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243968', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243913', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243908', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244316', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244200', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244055', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243997', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243939', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1892 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of hypertension? | In the context of hypertension, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149090', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149098', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.976 | Q34 | What are the names of the genes that are targeted by the drug Fostamatinib Disodium in the treatment of autoimmune thrombocytopenic purpura? | In the context of autoimmune thrombocytopenic purpura, the drug Fostamatinib Disodium targets the gene spleen associated tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%autoimmune thrombocytopenic purpura%" OR LOWER(efo_term) LIKE "%autoimmune thrombocytopenic purpura%") AND (LOWER(drugName) LIKE "%fostamatinib disodium%" OR LOWER(tradeNames_list) LIKE "%fostamatinib disodium%" OR LOWER(syns_list) LIKE "%fostamatinib disodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848773', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848794', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848801', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848808', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848822', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848829', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848836', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848850', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848857', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848864', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848871', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848885', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848892', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848899', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848906', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848913', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848920', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848927', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848843', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848787', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848759', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848745', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848738', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848878', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848815', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848780', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848766', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848752', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Purpura, Thrombocytopenic, Idiopathic', 'efo_term': 'autoimmune thrombocytopenic purpura', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.609 | Q34 | What are the names of the genes that are targeted by the drug Bupivacaine in the treatment of pain? | In the context of pain, the drug Bupivacaine targets the gene sodium voltage-gated channel alpha subunit 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%bupivacaine%" OR LOWER(tradeNames_list) LIKE "%bupivacaine%" OR LOWER(syns_list) LIKE "%bupivacaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_662994', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663742', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663810', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663266', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663606', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664014', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663198', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663334', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663878', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663946', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662926', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663470', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662790', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664030', 'drugName': 'Bupivacaine Hydrochloride', 'tradeNames_list': "['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kitBupivacaine hydrochloride preservative free', 'Marcain', 'MarcaineMarcaine hydrochloride', 'Marcaine hydrochloride preservative freeSensorcaine', 'Xaracoll']", 'syns_list': "['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochlorideBupivacaine hydrochloride hydrateBupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rsBupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631WIN 11,318', 'WIN-11318', 'Xaracoll']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663674', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663402', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663538', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663130', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663062', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662858', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663174', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663038', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663650', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663786', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663718', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662970', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663922', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663446', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662766', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663854', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663990', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663106', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662902', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663310', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663242', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663582', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663378', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662834', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663514', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662734', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663960', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663962', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663826', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663418', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663416', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663280', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663278', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662738', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663414', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663006', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663074', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663282', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663346', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663076', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663010', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663822', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663758', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663008', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663958', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662870', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663484', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662736', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662872', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663348', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662806', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663890', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663550', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663552', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663554', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663690', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663350', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662802', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663688', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663686', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663144', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662938', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663142', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663146', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663618', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663620', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663622', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662804', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663486', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663824', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663894', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662940', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663892', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663482', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663078', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662942', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663210', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663212', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663214', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663754', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Abdominal Pain', 'efo_term': 'Abdominal pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663756', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662874', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664018', 'drugName': 'Bupivacaine Hydrochloride', 'tradeNames_list': "['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kitBupivacaine hydrochloride preservative free', 'Marcain', 'MarcaineMarcaine hydrochloride', 'Marcaine hydrochloride preservative freeSensorcaine', 'Xaracoll']", 'syns_list': "['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochlorideBupivacaine hydrochloride hydrateBupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rsBupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631WIN 11,318', 'WIN-11318', 'Xaracoll']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663337', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663065', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663405', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1899 | Q34 | What are the names of the genes that are targeted by the drug Latanoprost in the treatment of glaucoma? | In the context of glaucoma, the drug Latanoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%latanoprost%" OR LOWER(tradeNames_list) LIKE "%latanoprost%" OR LOWER(syns_list) LIKE "%latanoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149109', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149116', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149118', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149122', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149112', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149106', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149103', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149102', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149124', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149111', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149108', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149105', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.91 | Q34 | What are the names of the genes that are targeted by the drug Palonosetron Hydrochloride in the treatment of Vomiting? | In the context of Vomiting, the drug Palonosetron Hydrochloride targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vomiting%" OR LOWER(efo_term) LIKE "%vomiting%") AND (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_list) LIKE "%palonosetron hydrochloride%" OR LOWER(syns_list) LIKE "%palonosetron hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205496', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205501', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205502', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205505', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205507', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205508', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205511', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205513', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205514', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205517', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205518', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205520', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205523', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205524', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205525', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205526', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205529', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205530', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205531', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205532', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205535', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205537', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205538', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205541', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205542', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205543', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205547', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205548', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205549', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205550', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205553', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205554', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205555', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205556', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205559', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205560', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205561', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205562', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205565', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205566', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205567', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205568', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205571', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205572', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205573', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205574', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205577', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205578', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205579', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205580', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205583', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205585', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205586', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205589', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205590', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205591', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205592', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205596', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205597', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205598', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205601', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205602', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205603', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205604', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205607', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205608', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205609', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205610', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205613', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205614', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205615', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205616', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205619', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205620', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205621', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205622', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205625', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205626', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205627', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205628', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205631', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205632', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205633', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205634', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205637', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205638', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205584', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205536', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205512', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205500', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205494', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205490', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205489', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205595', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205544', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205519', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205506', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205499', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205495', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205493', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.854 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Fever? | In the context of Fever, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fever%" OR LOWER(efo_term) LIKE "%fever%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834424', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834895', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835052', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835209', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835523', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835680', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835837', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835994', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834738', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834110', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833796', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833639', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835366', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834581', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834267', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833953', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1506 | Q34 | What are the names of the genes that are targeted by the drug Pralatrexate in the treatment of mature T-cell and NK-cell non-Hodgkin lymphoma? | In the context of mature T-cell and NK-cell non-Hodgkin lymphoma, the drug Pralatrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mature t-cell and nk-cell non-hodgkin lymphoma%" OR LOWER(efo_term) LIKE "%mature t-cell and nk-cell non-hodgkin lymphoma%") AND (LOWER(drugName) LIKE "%pralatrexate%" OR LOWER(tradeNames_list) LIKE "%pralatrexate%" OR LOWER(syns_list) LIKE "%pralatrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072535', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072459', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072440', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072497', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072516', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072478', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'mature T-cell and NK-cell non-Hodgkin lymphoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1898 | Q34 | What are the names of the genes that are targeted by the drug Latanoprostene Bunod in the treatment of ocular hypertension? | In the context of ocular hypertension, the drug Latanoprostene Bunod targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular hypertension%" OR LOWER(efo_term) LIKE "%ocular hypertension%") AND (LOWER(drugName) LIKE "%latanoprostene bunod%" OR LOWER(tradeNames_list) LIKE "%latanoprostene bunod%" OR LOWER(syns_list) LIKE "%latanoprostene bunod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149107', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149104', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149113', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149110', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.758 | Q34 | What are the names of the genes that are targeted by the drug Oxycodone in the treatment of drug dependence? | In the context of drug dependence, the drug Oxycodone targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%oxycodone%" OR LOWER(tradeNames_list) LIKE "%oxycodone%" OR LOWER(syns_list) LIKE "%oxycodone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_768124', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768223', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768256', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768289', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768355', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768388', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768421', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768487', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768520', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768553', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768586', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768652', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768685', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768718', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768751', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768784', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768817', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768850', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768883', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768916', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768949', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769015', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769048', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769081', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769114', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769147', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769213', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769246', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769279', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769312', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769345', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769378', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769411', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769444', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769477', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769510', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769543', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769576', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769609', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769642', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769675', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769708', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769741', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769774', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769807', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769840', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769873', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769906', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769939', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769972', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770005', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770071', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770104', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770137', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770170', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770203', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770236', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770302', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770335', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770368', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770401', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770434', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770467', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770500', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770533', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770566', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770599', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770632', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770665', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770698', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770731', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770764', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770797', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770830', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770863', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770896', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770929', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770962', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770995', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771028', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771061', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771094', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771127', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771160', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771193', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771226', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770038', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768982', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768454', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768190', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768058', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_767992', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_767959', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770269', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769180', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768619', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768322', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768157', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768091', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768025', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.502 | Q34 | What are the names of the genes that are targeted by the drug Viloxazine Hydrochloride in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Viloxazine Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%viloxazine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%viloxazine hydrochloride%" OR LOWER(syns_list) LIKE "%viloxazine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440674', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440677', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440678', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440679', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440676', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440672', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440670', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440669', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440680', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440675', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440673', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440671', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_list': "['Qelbree', 'Vivalan']", 'syns_list': "['ICI 58,834', 'ICI-58834', 'SPN-812', 'Spn-812', 'Viloxazine hclViloxazine hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1287 | Q34 | What are the names of the genes that are targeted by the drug Selpercatinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Selpercatinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%selpercatinib%" OR LOWER(tradeNames_list) LIKE "%selpercatinib%" OR LOWER(syns_list) LIKE "%selpercatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944410', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944431', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944438', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944445', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944459', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944466', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944473', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944487', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944494', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944501', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944508', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944522', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944529', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944536', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944543', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944550', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944557', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944564', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944571', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944578', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944585', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944599', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944606', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944613', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944620', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944627', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944641', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944648', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944655', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944662', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944669', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944676', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944683', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944690', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944697', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944704', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944711', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944718', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944725', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944732', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944739', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944746', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944753', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944760', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944767', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944774', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944781', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944788', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944795', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944802', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944809', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944823', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944830', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944837', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944844', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944851', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944858', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944872', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944879', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944886', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944893', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944900', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944907', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944914', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944921', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944928', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944935', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944942', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944949', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944956', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944963', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944970', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944977', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944984', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944991', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944998', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945005', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945012', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945019', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945026', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945033', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945040', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945047', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945054', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945061', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945068', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944816', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944592', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944480', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944424', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944396', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944382', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944375', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944865', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944634', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944515', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944452', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944417', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944403', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944389', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1336 | Q34 | What are the names of the genes that are targeted by the drug Odevixibat in the treatment of familial intrahepatic cholestasis? | In the context of familial intrahepatic cholestasis, the drug Odevixibat targets the gene solute carrier family 10 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial intrahepatic cholestasis%" OR LOWER(efo_term) LIKE "%familial intrahepatic cholestasis%") AND (LOWER(drugName) LIKE "%odevixibat%" OR LOWER(tradeNames_list) LIKE "%odevixibat%" OR LOWER(syns_list) LIKE "%odevixibat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992747', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992768', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992775', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992782', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992796', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992803', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992810', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992824', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992831', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992838', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992845', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992859', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992866', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992873', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992880', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992887', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992894', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992901', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992908', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992915', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992922', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992936', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992943', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992950', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992957', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992964', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992978', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992985', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992992', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992999', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_993006', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_993013', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992929', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992817', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992761', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992733', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992719', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992712', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992971', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992852', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992789', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992754', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992740', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_992726', 'drugName': 'Odevixibat', 'tradeNames_list': "['Bylvay']", 'syns_list': "['A-4250', 'A4250', 'AR-H064974', 'AZD-8294', 'AZD8294', 'OdevixibatOdevixibat sesquihydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholestasis, Intrahepatic', 'efo_term': 'familial intrahepatic cholestasis', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.12 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149657', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149756', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149789', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149822', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149888', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149921', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149954', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150020', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150053', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150086', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150119', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150185', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150218', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150251', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150284', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150317', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150350', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150383', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150416', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150449', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150482', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150548', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150581', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150614', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150647', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150680', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150746', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150779', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150812', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150845', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150878', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150911', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150944', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150977', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151010', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151043', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151076', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151109', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151142', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151175', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151208', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151241', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150515', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149987', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149723', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149591', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149525', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149492', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150713', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150152', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149855', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149690', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149624', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149558', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.399 | Q34 | What are the names of the genes that are targeted by the drug Fluocinolone Acetonide in the treatment of macular retinal edema? | In the context of macular retinal edema, the drug Fluocinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%macular retinal edema%" OR LOWER(efo_term) LIKE "%macular retinal edema%") AND (LOWER(drugName) LIKE "%fluocinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%fluocinolone acetonide%" OR LOWER(syns_list) LIKE "%fluocinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242242', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242258', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'syns_list': "['Flucinolone acetonide', 'Fluocinolide (acetate)', 'FluocinoloneFluocinolone acetonide', 'NSC-92339', 'Oto-synalar']", 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.286 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Hypercalcemia? | In the context of Hypercalcemia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercalcemia%" OR LOWER(efo_term) LIKE "%hypercalcemia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227741', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228596', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228881', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229166', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229736', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230021', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230306', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230876', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231161', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231446', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231731', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232301', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230591', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228311', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227171', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226601', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232016', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229451', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228026', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227456', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226886', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercalcemia', 'efo_term': 'Hypercalcemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1073 | Q34 | What are the names of the genes that are targeted by the drug Cangrelor Tetrasodium in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Cangrelor Tetrasodium targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%cangrelor tetrasodium%" OR LOWER(tradeNames_list) LIKE "%cangrelor tetrasodium%" OR LOWER(syns_list) LIKE "%cangrelor tetrasodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921002', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_921006', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920998', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920994', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920992', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_921004', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_921000', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920996', 'drugName': 'Cangrelor Tetrasodium', 'tradeNames_list': "['Kengreal']", 'syns_list': "['AR-C69931MX', 'Cangrelor', 'Cangrelor tetrasodiumCangrelor tetrasodium salt', 'Kengrexal']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1200 | Q34 | What are the names of the genes that are targeted by the drug Tepotinib Hydrochloride in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Tepotinib Hydrochloride targets the gene MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%tepotinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tepotinib hydrochloride%" OR LOWER(syns_list) LIKE "%tepotinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936138', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936142', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936134', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936130', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936128', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936140', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936136', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936132', 'drugName': 'Tepotinib Hydrochloride', 'tradeNames_list': "['Tepmetko']", 'syns_list': "['MSC2156119J', 'Msc2156119j', 'Tepotinib hydrochlorideTepotinib hydrochloride hydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1728 | Q34 | What are the names of the genes that are targeted by the drug Tafamidis Meglumine in the treatment of cardiomyopathy? | In the context of cardiomyopathy, the drug Tafamidis Meglumine targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiomyopathy%" OR LOWER(efo_term) LIKE "%cardiomyopathy%") AND (LOWER(drugName) LIKE "%tafamidis meglumine%" OR LOWER(tradeNames_list) LIKE "%tafamidis meglumine%" OR LOWER(syns_list) LIKE "%tafamidis meglumine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097629', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097624', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097639', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097634', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.695 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of Venous thrombosis? | In the context of Venous thrombosis, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%venous thrombosis%" OR LOWER(efo_term) LIKE "%venous thrombosis%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710422', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710476', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710480', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710505', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710534', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710538', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710563', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710592', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710596', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710621', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710625', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710654', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710679', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710683', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710708', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710712', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710737', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710741', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710766', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710770', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710567', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710451', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710393', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710364', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710360', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710650', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710509', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710447', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710418', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710389', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1616 | Q34 | What are the names of the genes that are targeted by the drug Bivalirudin in the treatment of thrombotic disease? | In the context of thrombotic disease, the drug Bivalirudin targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombotic disease%" OR LOWER(efo_term) LIKE "%thrombotic disease%") AND (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_list) LIKE "%bivalirudin%" OR LOWER(syns_list) LIKE "%bivalirudin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092330', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092313', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092364', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092347', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'syns_list': "['BG-8967', 'BG8967', 'Bivalirudin']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1858 | Q34 | What are the names of the genes that are targeted by the drug Rosuvastatin Calcium in the treatment of hyperlipidemia? | In the context of hyperlipidemia, the drug Rosuvastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperlipidemia%" OR LOWER(efo_term) LIKE "%hyperlipidemia%") AND (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_list) LIKE "%rosuvastatin calcium%" OR LOWER(syns_list) LIKE "%rosuvastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104169', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104152', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104254', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104220', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104135', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104237', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104186', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104203', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104196', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104213', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104247', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104162', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104145', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104128', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104230', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104179', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hyperlipidemia, Familial Combined', 'efo_term': 'Combined hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.694 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710504', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710591', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710620', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710649', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710707', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710736', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710765', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710562', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710446', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710388', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710359', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710678', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710533', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710475', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710417', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.857 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of Muscle spasm? | In the context of Muscle spasm, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle spasm%" OR LOWER(efo_term) LIKE "%muscle spasm%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834427', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834898', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835055', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835212', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835526', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835683', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835840', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835997', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834741', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834113', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833799', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833642', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835369', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834584', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834270', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833956', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.161 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of atopic eczema? | In the context of atopic eczema, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218667', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219291', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219499', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219707', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220123', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220331', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220539', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220747', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219083', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218251', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217835', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217627', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219915', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218875', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218459', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218043', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.901 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of migraine disorder? | In the context of migraine disorder, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838138', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838189', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838206', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838223', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838257', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838274', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838291', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838308', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838172', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838104', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838070', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838053', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838240', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838155', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838121', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838087', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1561 | Q34 | What are the names of the genes that are targeted by the drug Ambrisentan in the treatment of idiopathic and/or familial pulmonary arterial hypertension? | In the context of idiopathic and/or familial pulmonary arterial hypertension, the drug Ambrisentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%idiopathic and/or familial pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%ambrisentan%" OR LOWER(tradeNames_list) LIKE "%ambrisentan%" OR LOWER(syns_list) LIKE "%ambrisentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084111', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084147', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084159', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084171', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084135', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084087', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084063', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084051', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084183', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084123', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084099', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084075', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.259 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222610', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222745', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222790', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222835', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222925', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222970', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223015', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223105', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223150', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223195', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223240', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223330', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223375', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223420', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223465', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223510', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223555', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223600', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223645', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223690', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223735', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223825', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223870', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223915', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223960', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224005', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224095', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224140', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224185', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224230', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224275', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224320', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224365', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224410', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224455', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224500', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224545', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224590', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224635', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224680', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224725', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224770', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224815', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224860', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224905', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224950', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224995', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225040', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225085', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225130', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225175', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225265', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225310', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225355', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225400', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225220', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223780', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222700', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222520', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222430', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222385', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223060', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224050', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223285', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222880', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222655', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222565', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222475', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.337 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of posterior uveitis? | In the context of posterior uveitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%posterior uveitis%" OR LOWER(efo_term) LIKE "%posterior uveitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227793', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228648', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228933', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229218', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229788', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230073', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230928', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231213', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228363', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227223', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226653', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226368', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229503', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228078', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227508', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226938', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1862 | Q34 | What are the names of the genes that are targeted by the drug Pitavastatin Magnesium in the treatment of hyperlipidemia? | In the context of hyperlipidemia, the drug Pitavastatin Magnesium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperlipidemia%" OR LOWER(efo_term) LIKE "%hyperlipidemia%") AND (LOWER(drugName) LIKE "%pitavastatin magnesium%" OR LOWER(tradeNames_list) LIKE "%pitavastatin magnesium%" OR LOWER(syns_list) LIKE "%pitavastatin magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104304', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104306', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104308', 'drugName': 'Pitavastatin Magnesium', 'tradeNames_list': "['Zypitamag']", 'syns_list': "['Pitavastatin magnesium']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1046 | Q34 | What are the names of the genes that are targeted by the drug Levetiracetam in the treatment of epilepsy? | In the context of epilepsy, the drug Levetiracetam targets the gene calcium voltage-gated channel subunit alpha1 B and synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%levetiracetam%" OR LOWER(tradeNames_list) LIKE "%levetiracetam%" OR LOWER(syns_list) LIKE "%levetiracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_915656', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915217', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915525', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914862', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914733', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916053', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915129', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914950', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914777', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915258', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915568', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915346', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915038', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916008', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915786', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915082', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915085', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916094', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914908', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915742', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915744', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915173', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915436', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914952', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915522', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914821', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915261', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915877', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914996', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915566', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914732', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915610', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915349', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915918', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915040', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916050', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914865', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916006', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915965', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916009', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915084', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915700', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915698', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916138', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916052', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915126', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915128', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916097', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914909', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916096', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915745', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915172', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915434', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914730', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915524', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914820', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915214', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915832', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914953', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915480', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915478', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915830', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915260', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915789', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915481', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915962', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914774', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915302', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915304', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915876', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914997', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915874', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915612', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915921', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915348', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915569', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914776', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915920', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914864', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915390', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915392', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916140', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915041', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915657', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915654', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916182', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916141', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915964', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915833', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915613', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915437', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915170', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914818', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915216', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915788', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915305', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915701', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914906', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914994', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915393', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.519 | Q34 | What are the names of the genes that are targeted by the drug Memantine Hydrochloride in the treatment of Dementia? | In the context of Dementia, the drug Memantine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dementia%" OR LOWER(efo_term) LIKE "%dementia%") AND (LOWER(drugName) LIKE "%memantine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%memantine hydrochloride%" OR LOWER(syns_list) LIKE "%memantine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455455', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455693', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455371', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455105', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455343', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455007', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455399', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455567', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455147', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455511', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455315', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455245', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455595', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_454993', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455091', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455329', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455637', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455749', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455609', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455413', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455189', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455441', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455427', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455231', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455497', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455287', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455539', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455133', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455553', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455063', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455581', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455357', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455119', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455385', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455273', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455665', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455301', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455021', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455735', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455203', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455259', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455469', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455217', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455525', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455175', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455623', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455763', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455707', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455679', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455049', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455721', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455483', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455161', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455077', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455651', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455035', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dementia', 'efo_term': 'Dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455384', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455188', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455398', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455090', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455412', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455454', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455230', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455468', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455482', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455118', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455426', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455496', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455510', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455258', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455538', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455062', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455132', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455552', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455566', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455286', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455580', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455594', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455146', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455300', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455272', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455608', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455622', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455314', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455636', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455524', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455650', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455006', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455076', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455160', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455244', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455328', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455664', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455678', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455342', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455174', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455356', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455370', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455034', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455202', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Frontotemporal Dementia', 'efo_term': 'frontotemporal dementia', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1359 | Q34 | What are the names of the genes that are targeted by the drug Acalabrutinib in the treatment of neoplasm? | In the context of neoplasm, the drug Acalabrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%acalabrutinib%" OR LOWER(tradeNames_list) LIKE "%acalabrutinib%" OR LOWER(syns_list) LIKE "%acalabrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_994023', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994989', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994921', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994000', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993978', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994852', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994185', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994161', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994438', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994484', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994599', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994690', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994046', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994897', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994737', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994898', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994875', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994231', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994828', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994829', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994139', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994208', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994392', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994092', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994483', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994024', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994254', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994668', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994115', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994621', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994622', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994714', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994300', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994644', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994138', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994760', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994047', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994369', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994162', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994943', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994323', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994736', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994806', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993977', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994967', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994990', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994184', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994759', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994070', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994322', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994944', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994207', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994368', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994346', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994415', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994391', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994414', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994552', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994093', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994461', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994460', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994530', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994253', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994529', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994507', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994783', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994575', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994598', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994276', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994667', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994116', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994645', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994920', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994782', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994299', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994713', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994691', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994805', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994553', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994437', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994576', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994345', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994001', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994874', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994069', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994230', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994506', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994277', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994851', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994966', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994012', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994065', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994173', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994178', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994180', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994017', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994193', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994078', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994196', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994201', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1022 | Q34 | What are the names of the genes that are targeted by the drug Tiotropium Bromide in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Tiotropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%tiotropium bromide%" OR LOWER(tradeNames_list) LIKE "%tiotropium bromide%" OR LOWER(syns_list) LIKE "%tiotropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857913', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857946', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857957', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857968', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857990', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858001', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858012', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858034', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858045', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858056', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858067', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858089', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858100', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858111', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858122', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858133', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858144', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858155', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858166', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858177', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858188', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858210', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858221', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858232', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858243', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858254', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858199', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858023', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857935', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857891', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857869', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857858', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858265', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858078', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857979', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857924', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857902', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857880', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.773 | Q34 | What are the names of the genes that are targeted by the drug Naloxone Hydrochloride in the treatment of septic shock? | In the context of septic shock, the drug Naloxone Hydrochloride targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%septic shock%" OR LOWER(efo_term) LIKE "%septic shock%") AND (LOWER(drugName) LIKE "%naloxone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%naloxone hydrochloride%" OR LOWER(syns_list) LIKE "%naloxone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_789395', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789416', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789423', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789430', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789444', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789451', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789458', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789472', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789479', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789486', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789493', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789507', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789514', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789521', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789528', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789535', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789542', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789549', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789556', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789563', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789570', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789584', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789591', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789598', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789605', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789612', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789626', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789633', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789640', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789647', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789654', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789661', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789668', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789675', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789682', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789689', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789696', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789703', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789710', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789717', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789724', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789731', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789738', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789745', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789752', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789759', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789766', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789773', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789780', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789787', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789794', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789808', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789815', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789822', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789829', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789836', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789843', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789857', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789864', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789871', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789878', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789885', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789892', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789899', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789906', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789913', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789920', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789927', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789934', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789941', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789948', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789955', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789962', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789969', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789976', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789983', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789990', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789997', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790004', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790011', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790018', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_790025', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790032', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790039', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790046', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_790053', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_789801', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789577', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789465', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789409', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789381', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789367', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789360', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789850', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789619', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789500', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789437', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789402', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789388', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789374', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_list': "['Evzio', 'Evzio (autoinjector)', 'Kloxxado', 'Nalone', 'NaloxoneNaloxone hydrochloride', 'Naloxone hydrochloride (autoinjector)', 'NarcanNarcan neonatal', 'Narconil', 'Prenoxad', 'Zimhi']", 'syns_list': "['Anhydrous naloxone hydrochloride', 'EN-15304', 'NIH 7890', 'NSC-757109Naloxone hcl', 'Naloxone hydrochlorideNaloxone hydrochloride anhydrous', 'Naloxoni hydrochloridum anhydrousNarcanti']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1733 | Q34 | What are the names of the genes that are targeted by the drug Inotersen Sodium in the treatment of amyloidosis? | In the context of amyloidosis, the drug Inotersen Sodium targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amyloidosis%" OR LOWER(efo_term) LIKE "%amyloidosis%") AND (LOWER(drugName) LIKE "%inotersen sodium%" OR LOWER(tradeNames_list) LIKE "%inotersen sodium%" OR LOWER(syns_list) LIKE "%inotersen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097659', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097647', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097644', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097653', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097656', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097650', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.766 | Q34 | What are the names of the genes that are targeted by the drug Fentanyl in the treatment of cancer? | In the context of cancer, the drug Fentanyl targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%fentanyl%" OR LOWER(tradeNames_list) LIKE "%fentanyl%" OR LOWER(syns_list) LIKE "%fentanyl%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_786255', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785389', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786103', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785411', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785433', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785875', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785455', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785477', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786027', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785334', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786403', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786179', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786217', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786745', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786707', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785837', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785587', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786821', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785367', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785913', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785631', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785378', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785989', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785675', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786327', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785312', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785719', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786555', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785510', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786141', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785757', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786593', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785532', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786369', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785795', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786787', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785323', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786711', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785833', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786783', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785576', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786749', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785871', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786859', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785598', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785609', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785909', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786825', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785620', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786445', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785947', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785642', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785653', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785985', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786331', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785664', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786293', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786479', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785686', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785488', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786061', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786483', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785499', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785565', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786099', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786669', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785723', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786365', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786137', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786521', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785521', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785356', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786175', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786635', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785761', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786559', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786213', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786631', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785543', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786597', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786251', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786863', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785799', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785554', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786289', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786901', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786897', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786673', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786517', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786407', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785951', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785466', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785301', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786023', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786065', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cancer Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785345', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786441', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785444', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785400', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785422', 'drugName': 'Fentanyl Citrate', 'tradeNames_list': "['Abstral', 'Actiq', 'Fentanyl', 'Fentanyl citrateFentanyl citrate preservative free', 'Fentora', 'Lazanda', 'OnsolisSublimaze', 'Sublimaze preservative free', 'Thalamonal']", 'syns_list': "['Fentanyl buccal', 'Fentanyl citrate', 'Fentanyl citrate cii', 'InstanylKw-2246', 'Leptanal', 'MCN-JR-4263-49', 'R-4263']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1256 | Q34 | What are the names of the genes that are targeted by the drug Alpelisib in the treatment of cancer? | In the context of cancer, the drug Alpelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%alpelisib%" OR LOWER(tradeNames_list) LIKE "%alpelisib%" OR LOWER(syns_list) LIKE "%alpelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939757', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939754', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939715', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939547', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939712', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939670', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939565', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939610', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939649', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939523', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939733', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939628', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939694', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939526', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939544', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939589', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939652', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939673', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939568', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939736', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939691', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939586', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939607', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939631', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939605', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939542', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939521', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939752', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939584', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939689', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939710', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939668', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939563', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939626', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939647', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939731', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939603', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939687', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939624', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939708', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939561', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939519', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939729', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939750', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939540', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939645', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939582', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939666', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939638', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939574', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939512', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939657', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939658', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939659', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939575', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939680', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939552', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939637', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939594', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939678', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939679', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939595', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939510', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939511', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939531', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939553', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939699', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939701', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939554', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939720', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939742', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939532', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939615', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939721', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939700', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939722', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939616', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Oropharyngeal Neoplasms', 'efo_term': 'oropharynx cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939617', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939741', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939533', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939636', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939743', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939573', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_939596', 'drugName': 'Alpelisib', 'tradeNames_list': "['Piqray', 'Vijoice']", 'syns_list': "['Alpelisib', 'BYL-719', 'BYL719', 'Byl-719', 'NVP-BYL719', 'Vijoice']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1212 | Q34 | What are the names of the genes that are targeted by the drug Propranolol Hydrochloride in the treatment of cardiac arrhythmia? | In the context of cardiac arrhythmia, the drug Propranolol Hydrochloride targets the gene adrenoceptor beta 2 and adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiac arrhythmia%" OR LOWER(efo_term) LIKE "%cardiac arrhythmia%") AND (LOWER(drugName) LIKE "%propranolol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%propranolol hydrochloride%" OR LOWER(syns_list) LIKE "%propranolol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937043', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937020', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937089', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937066', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'syns_list': "['AY 64043', 'AY-64043', 'ICI 45520', 'ICI-45520', 'NSC-91523Propranolol hydrochloride']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1454 | Q34 | What are the names of the genes that are targeted by the drug Lifitegrast in the treatment of eye disease? | In the context of eye disease, the drug Lifitegrast targets the gene integrin subunit alpha L and integrin subunit beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye disease%" OR LOWER(efo_term) LIKE "%eye disease%") AND (LOWER(drugName) LIKE "%lifitegrast%" OR LOWER(tradeNames_list) LIKE "%lifitegrast%" OR LOWER(syns_list) LIKE "%lifitegrast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053375', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053387', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053391', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053395', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053403', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053407', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053411', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053419', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053423', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053427', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053431', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053439', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053443', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053447', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053451', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053455', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053459', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053463', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053467', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053471', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053475', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053479', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053415', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053383', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053367', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053359', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053355', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053435', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_1053399', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053379', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053371', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}, {'UUID': 'DrugTargetsIndication121923_text_1053363', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'syns_list': "['Lifitegrast', 'SAR 1118', 'SAR-1118', 'SHP-606', 'SHP606']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1966 | Q34 | What are the names of the genes that are targeted by the drug Mitapivat Sulfate in the treatment of familial hemolytic anemia? | In the context of familial hemolytic anemia, the drug Mitapivat Sulfate targets the gene pyruvate kinase L/R. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hemolytic anemia%" OR LOWER(efo_term) LIKE "%familial hemolytic anemia%") AND (LOWER(drugName) LIKE "%mitapivat sulfate%" OR LOWER(tradeNames_list) LIKE "%mitapivat sulfate%" OR LOWER(syns_list) LIKE "%mitapivat sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193478', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193481', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193482', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193483', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193485', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193486', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193487', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193489', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193490', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193491', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193492', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193488', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193480', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193476', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193474', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193473', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193493', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193484', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193479', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193477', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}, {'UUID': 'DrugTargetsIndication121923_text_1193475', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'syns_list': "['AG-348 HEMISULFATE SESQUIHYDRATE', 'AG-348 sulfate hydrateMitapivat sulfate', 'Pyrukynd']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.525 | Q34 | What are the names of the genes that are targeted by the drug Fexofenadine Hydrochloride in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Fexofenadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%fexofenadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fexofenadine hydrochloride%" OR LOWER(syns_list) LIKE "%fexofenadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455785', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455783', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455791', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455789', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.23 | Q34 | What are the names of the genes that are targeted by the drug Fenfluramine Hydrochloride in the treatment of Dravet syndrome? | In the context of Dravet syndrome, the drug Fenfluramine Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1D and sigma non-opioid intracellular receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dravet syndrome%" OR LOWER(efo_term) LIKE "%dravet syndrome%") AND (LOWER(drugName) LIKE "%fenfluramine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fenfluramine hydrochloride%" OR LOWER(syns_list) LIKE "%fenfluramine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155526', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155535', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155538', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155541', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155547', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155550', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155553', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155559', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155562', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155565', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155568', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155574', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155577', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155580', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155583', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155586', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155589', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155592', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155595', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155598', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155601', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155607', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155610', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155613', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155616', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155619', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155625', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155628', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155631', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155634', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155637', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155640', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155643', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155646', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155649', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155652', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155655', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155658', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155661', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155664', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155667', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155670', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155673', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155676', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155679', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155682', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155685', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155688', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155691', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155694', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155697', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155703', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155706', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155709', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155712', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155715', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155718', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155724', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155727', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155730', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155733', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155736', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155739', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155742', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155745', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155748', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155751', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155700', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155604', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155556', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155532', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155520', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155514', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155511', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155721', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'SIGMAR1', 'approvedName': 'sigma non-opioid intracellular receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_155622', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR1D', 'approvedName': '5-hydroxytryptamine receptor 1D'}, {'UUID': 'DrugTargetsIndication121923_text_155571', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155544', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155529', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155523', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_155517', 'drugName': 'Fenfluramine Hydrochloride', 'tradeNames_list': "['Fintepla', 'Ponderax', 'Ponderax pacaps', 'Pondimin']", 'syns_list': "['AHR-3002', 'Dl-fenfluramine hydrochloride', 'Fenfluramine hclFenfluramine hydrochloride', 'Ganal', 'HHR-965']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Myoclonic', 'efo_term': 'Dravet syndrome', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.358 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of atopic eczema? | In the context of atopic eczema, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232528', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232609', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232636', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232663', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232717', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232744', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232771', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232825', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232852', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232879', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232906', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232960', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232987', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233014', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233041', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233068', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233095', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233122', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233149', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233176', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233203', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233257', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233284', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233311', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233338', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233365', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233419', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233446', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233473', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233500', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233527', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233554', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233581', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233608', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233635', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233662', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233689', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233716', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233743', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233770', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233797', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233824', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233851', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233878', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233905', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233932', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233959', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233986', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234013', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234040', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234067', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234121', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234148', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234175', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234202', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234229', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234256', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234310', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234337', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234364', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234391', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234418', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234445', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234472', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234499', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234526', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234553', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234580', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234607', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234634', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234661', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234688', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234715', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234742', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234769', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234796', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234823', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234850', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234877', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234904', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234931', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234958', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234985', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235012', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235039', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235066', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234094', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233230', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232798', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232582', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232474', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232420', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232393', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234283', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233392', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232933', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232690', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232555', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232501', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232447', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1288 | Q34 | What are the names of the genes that are targeted by the drug Selpercatinib in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Selpercatinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%selpercatinib%" OR LOWER(tradeNames_list) LIKE "%selpercatinib%" OR LOWER(syns_list) LIKE "%selpercatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944411', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944432', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944439', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944446', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944460', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944467', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944474', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944488', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944495', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944502', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944509', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944523', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944530', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944537', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944544', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944551', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944558', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944565', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944572', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944579', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944586', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944600', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944607', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944614', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944621', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944628', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944642', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944649', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944656', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944663', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944670', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944677', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944684', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944691', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944698', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944705', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944712', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944719', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944726', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944733', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944740', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944747', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944754', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944761', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944768', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944775', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944782', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944789', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944796', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944803', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944810', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944824', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944831', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944838', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944845', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944852', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944859', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944873', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944880', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944887', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944894', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944901', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944908', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944915', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944922', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944929', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944936', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944943', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944950', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944957', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944964', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944971', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944978', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944985', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944992', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944999', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945006', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945013', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945020', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945027', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945034', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945041', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945048', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945055', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945062', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945069', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944817', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944593', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944481', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944425', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944397', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944383', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944376', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944866', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944635', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944516', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944453', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944418', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944404', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944390', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1323 | Q34 | What are the names of the genes that are targeted by the drug Venetoclax in the treatment of chronic lymphocytic leukemia? | In the context of chronic lymphocytic leukemia, the drug Venetoclax targets the gene BCL2 apoptosis regulator. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic lymphocytic leukemia%" OR LOWER(efo_term) LIKE "%chronic lymphocytic leukemia%") AND (LOWER(drugName) LIKE "%venetoclax%" OR LOWER(tradeNames_list) LIKE "%venetoclax%" OR LOWER(syns_list) LIKE "%venetoclax%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_989881', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989995', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990033', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990071', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990147', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990185', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990223', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990299', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990337', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990375', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990413', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990489', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990527', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990565', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990603', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990641', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990679', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990717', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990755', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990793', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990831', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990907', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990945', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990983', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_991021', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990869', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989957', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989805', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989729', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989691', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990261', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990451', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990109', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989919', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989843', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989767', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1668 | Q34 | What are the names of the genes that are targeted by the drug Tasimelteon in the treatment of sleep-wake disorder? | In the context of sleep-wake disorder, the drug Tasimelteon targets the gene melatonin receptor 1A and melatonin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sleep-wake disorder%" OR LOWER(efo_term) LIKE "%sleep-wake disorder%") AND (LOWER(drugName) LIKE "%tasimelteon%" OR LOWER(tradeNames_list) LIKE "%tasimelteon%" OR LOWER(syns_list) LIKE "%tasimelteon%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094713', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094737', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094745', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094753', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094769', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094777', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094785', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094801', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094809', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094817', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094825', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094841', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094849', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094857', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094865', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094873', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094881', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094889', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094897', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094905', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094913', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094929', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094937', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094945', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094953', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094961', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094977', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094985', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094993', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095001', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095009', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095017', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095025', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095033', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095041', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095049', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095057', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095065', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095073', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095081', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095089', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095097', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095105', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095113', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095121', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095129', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095137', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095145', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095153', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095161', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095169', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095185', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095193', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095201', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095209', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095217', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095225', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095241', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095249', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095257', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095265', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095273', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095281', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095289', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095297', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095305', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095313', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095321', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095329', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095337', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095345', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095353', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095361', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095369', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095377', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095385', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095177', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1094921', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094793', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094729', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094697', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094681', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094673', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095233', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1094969', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094833', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094761', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094721', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094705', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094689', 'drugName': 'Tasimelteon', 'tradeNames_list': "['Hetlioz', 'Hetlioz lq']", 'syns_list': "['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Wake Disorders', 'efo_term': 'sleep-wake disorder', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.342 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227798', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228653', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228938', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229223', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229793', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230078', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230363', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230933', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231218', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231503', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231788', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230648', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228368', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227228', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226658', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226373', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232073', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229508', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228083', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227513', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226943', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.435 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Carvedilol targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_list) LIKE "%carvedilol%" OR LOWER(syns_list) LIKE "%carvedilol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_357138', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357234', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357266', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357298', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357362', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357394', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357426', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357490', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357522', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357554', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357586', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357650', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357682', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357714', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357746', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357778', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357810', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357842', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357874', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357906', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357938', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358002', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358034', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358066', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358098', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358130', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358194', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358226', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358258', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358290', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358322', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358354', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358386', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358418', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358450', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358482', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358514', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358546', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358578', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358610', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358642', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358674', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358706', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358738', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358770', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358802', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358834', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358866', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358898', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358930', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358962', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359026', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359058', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359090', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359122', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359154', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359186', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359250', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359282', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359314', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359346', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359378', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359410', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359442', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359474', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359506', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359538', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359570', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359602', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359634', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359666', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359698', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359730', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359762', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359794', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359826', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359858', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359890', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359922', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359954', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359986', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360018', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360050', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360082', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360114', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360146', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_358994', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357970', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357458', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357202', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357074', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357010', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_356978', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359218', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358162', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357618', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357330', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357170', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357106', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357042', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.477 | Q34 | What are the names of the genes that are targeted by the drug Ephedrine Sulfate in the treatment of common cold? | In the context of common cold, the drug Ephedrine Sulfate targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%ephedrine sulfate%" OR LOWER(tradeNames_list) LIKE "%ephedrine sulfate%" OR LOWER(syns_list) LIKE "%ephedrine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418288', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_418303', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_418308', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_418313', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_418323', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_418328', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_418333', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418343', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418348', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418338', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418298', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_418268', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_418263', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_418278', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_418318', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_418293', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_418283', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_418273', 'drugName': 'Ephedrine Sulfate', 'tradeNames_list': "['Akovaz', 'Corphedra', 'Emerphed', 'Expansyl', 'Franol plus', 'Franol-plusIsofedrol']", 'syns_list': "['Ephedrine sulfate', 'Ephedrine sulphate', 'Ephedrini sulfas']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.219 | Q34 | What are the names of the genes that are targeted by the drug Fluocinonide in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Fluocinonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%fluocinonide%" OR LOWER(tradeNames_list) LIKE "%fluocinonide%" OR LOWER(syns_list) LIKE "%fluocinonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220808', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'syns_list': "['Fluocinolide', 'Fluocinonide', 'NSC-101791']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220813', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'syns_list': "['Fluocinolide', 'Fluocinonide', 'NSC-101791']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220818', 'drugName': 'Fluocinonide', 'tradeNames_list': "['Fluocinonide', 'Fluocinonide emulsified base', 'Lidex', 'Lidex-e', 'MetosynMetosyn fapg', 'Vanos']", 'syns_list': "['Fluocinolide', 'Fluocinonide', 'NSC-101791']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.918 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of muscle cramp? | In the context of muscle cramp, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle cramp%" OR LOWER(efo_term) LIKE "%muscle cramp%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838548', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838671', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838712', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838753', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838835', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838876', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838917', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838999', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839040', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839081', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839122', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839204', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839245', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839286', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839327', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839368', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839409', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839450', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839491', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839532', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839573', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839655', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839696', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839614', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838958', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838630', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838384', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838343', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838466', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839163', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838794', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838589', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838507', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838425', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1236 | Q34 | What are the names of the genes that are targeted by the drug Mirabegron in the treatment of Polyuria? | In the context of Polyuria, the drug Mirabegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polyuria%" OR LOWER(efo_term) LIKE "%polyuria%") AND (LOWER(drugName) LIKE "%mirabegron%" OR LOWER(tradeNames_list) LIKE "%mirabegron%" OR LOWER(syns_list) LIKE "%mirabegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937773', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937821', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937837', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937853', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937885', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937901', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937917', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937949', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937965', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937981', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937997', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938029', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938045', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938061', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938077', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938093', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938109', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938125', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938141', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938157', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938173', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938205', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938221', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938237', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938253', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938189', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937805', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937741', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937709', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937693', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937933', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938013', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937869', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937789', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937757', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937725', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyuria', 'efo_term': 'Polyuria', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1582 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of hamartoma? | In the context of hamartoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hamartoma%" OR LOWER(efo_term) LIKE "%hamartoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1087125', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088745', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085640', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087800', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088340', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090230', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089690', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089960', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086585', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089555', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089420', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086855', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085910', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089015', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088205', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085235', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088475', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088070', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086450', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084965', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086180', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089285', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087260', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085775', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085370', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085100', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086045', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090635', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090365', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090500', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085505', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086315', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087935', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087665', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086990', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087530', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089150', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089825', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087395', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088880', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088610', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090095', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086720', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberous Sclerosis', 'efo_term': 'hamartoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086343', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087828', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087963', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084993', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085668', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086478', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088098', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088233', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086613', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088368', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089043', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088503', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085263', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086748', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088638', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090528', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088773', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084858', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085128', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085398', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087018', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089178', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089313', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085803', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089448', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089583', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086073', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087288', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089718', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089853', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087423', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087153', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085938', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089988', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090123', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085533', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086208', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087558', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090258', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090393', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087693', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088908', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086883', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hamartoma Syndrome, Multiple', 'efo_term': 'PTEN hamartoma tumor syndrome', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1018 | Q34 | What are the names of the genes that are targeted by the drug Revefenacin in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Revefenacin targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%revefenacin%" OR LOWER(tradeNames_list) LIKE "%revefenacin%" OR LOWER(syns_list) LIKE "%revefenacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857810', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857822', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857826', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857830', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857838', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857842', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857846', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857850', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857818', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857802', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857794', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857790', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857834', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857814', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857806', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857798', 'drugName': 'Revefenacin', 'tradeNames_list': "['Yupelri']", 'syns_list': "['GSK-1160724', 'GSK1160724', 'Revefenacin', 'TD-4208']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1930 | Q34 | What are the names of the genes that are targeted by the drug Azacitidine in the treatment of cancer? | In the context of cancer, the drug Azacitidine targets the gene DNA methyltransferase 1 and DNA methyltransferase 3 alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%azacitidine%" OR LOWER(tradeNames_list) LIKE "%azacitidine%" OR LOWER(syns_list) LIKE "%azacitidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192102', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191916', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191978', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192040', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191902', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191883', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191958', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192024', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191896', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191963', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192025', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192026', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192086', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191901', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192087', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192069', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192088', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192007', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191900', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191945', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191962', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192020', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191964', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192082', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191873', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191935', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192059', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191997', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.95 | Q34 | What are the names of the genes that are targeted by the drug Palonosetron Hydrochloride in the treatment of post operative nausea and vomiting? | In the context of post operative nausea and vomiting, the drug Palonosetron Hydrochloride targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%post operative nausea and vomiting%" OR LOWER(efo_term) LIKE "%post operative nausea and vomiting%") AND (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_list) LIKE "%palonosetron hydrochloride%" OR LOWER(syns_list) LIKE "%palonosetron hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205523', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205541', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205547', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205553', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205565', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205571', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205577', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205589', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205595', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205601', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205607', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205619', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205625', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205631', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205637', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205643', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205649', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205655', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205661', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205667', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205673', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205685', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205691', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205697', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205703', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205709', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205721', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205727', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205733', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205739', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205679', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205583', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205535', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205511', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205499', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205493', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205715', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205613', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205559', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205529', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205517', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205505', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1015 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of asthma? | In the context of asthma, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857481', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1077 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Cypionate in the treatment of hypogonadism? | In the context of hypogonadism, the drug Testosterone Cypionate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone cypionate%" OR LOWER(tradeNames_list) LIKE "%testosterone cypionate%" OR LOWER(syns_list) LIKE "%testosterone cypionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921015', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1100 | Q34 | What are the names of the genes that are targeted by the drug Testosterone in the treatment of hypogonadism? | In the context of hypogonadism, the drug Testosterone targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone%" OR LOWER(tradeNames_list) LIKE "%testosterone%" OR LOWER(syns_list) LIKE "%testosterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921393', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921402', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921411', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921420', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921429', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921438', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921456', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921465', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921474', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921483', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921492', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921501', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921510', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921519', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921528', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921537', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921546', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921555', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921564', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921573', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921582', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921591', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921600', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921609', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921618', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921627', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921636', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921645', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921654', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921663', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921681', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921690', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921699', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921708', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921717', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921726', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921735', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921744', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921753', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921762', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921771', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921780', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921789', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921798', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921015', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921672', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921447', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921384', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921375', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921366', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1571 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1087114', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088734', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085629', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087789', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088329', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090219', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089679', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089949', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086574', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089544', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089409', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086844', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085899', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089004', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088194', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085224', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088464', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088059', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086439', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084954', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086169', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089274', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087249', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085764', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085359', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085089', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086034', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090624', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090354', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090489', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085494', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086304', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087924', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087654', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086979', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087519', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089139', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089814', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087384', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088869', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088599', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090084', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086709', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086333', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087818', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087953', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084983', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085658', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086468', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088088', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088223', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086603', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088358', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089033', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088493', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085253', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086738', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088628', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090518', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088763', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084848', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085118', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085388', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087008', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089168', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089303', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085793', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089438', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089573', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086063', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087278', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089708', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089843', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087413', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087143', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085928', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089978', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090113', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085523', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086198', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087548', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090248', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090383', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087683', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088898', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086873', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1319 | Q34 | What are the names of the genes that are targeted by the drug Nitric Oxide in the treatment of respiratory system disease? | In the context of respiratory system disease, the drug Nitric Oxide targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%respiratory system disease%" OR LOWER(efo_term) LIKE "%respiratory system disease%") AND (LOWER(drugName) LIKE "%nitric oxide%" OR LOWER(tradeNames_list) LIKE "%nitric oxide%" OR LOWER(syns_list) LIKE "%nitric oxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_974422', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974584', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974638', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974692', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974800', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974854', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974908', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975016', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975070', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975124', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975178', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975286', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975340', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975394', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975448', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975502', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975556', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975610', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975664', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975718', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975772', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975880', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975934', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975988', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976042', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976096', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976204', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976258', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976312', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976366', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976420', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976474', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976528', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976582', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976636', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976690', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976744', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976798', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976852', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976906', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976960', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977014', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977068', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977122', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977176', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977230', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977284', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977338', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977392', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977446', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977500', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977608', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977662', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977716', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977770', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977824', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977878', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977986', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_978040', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978094', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978148', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978202', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978256', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978310', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978364', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978418', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978472', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978526', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978580', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978634', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978688', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978742', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978796', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978850', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978904', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_978958', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979012', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979066', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979120', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979174', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979228', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979282', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979336', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979390', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979444', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_979498', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_977554', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975826', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974962', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974530', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974314', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974206', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974152', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_977932', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_976150', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_975232', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974746', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974476', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974368', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_974260', 'drugName': 'Nitric Oxide', 'tradeNames_list': "['Genosyl', 'Inomax']", 'syns_list': "['Amidogen, oxo-', 'Inovent', 'Nitric oxide', 'Nitric oxide trimerNitrogen oxide (no)', 'Nitrosyl radical', 'OHM-11771']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.701 | Q34 | What are the names of the genes that are targeted by the drug Betrixaban in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Betrixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%betrixaban%" OR LOWER(tradeNames_list) LIKE "%betrixaban%" OR LOWER(syns_list) LIKE "%betrixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710818', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710842', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710850', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710858', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710834', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710802', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710786', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710778', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710866', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710826', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710810', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710794', 'drugName': 'Betrixaban', 'tradeNames_list': "['Bevyxxa']", 'syns_list': "['Betrixaban', 'Betrixaban maleate', 'PRT-054021', 'PRT054021']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1776 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of metastatic prostate cancer? | In the context of metastatic prostate cancer, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic prostate cancer%" OR LOWER(efo_term) LIKE "%metastatic prostate cancer%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099873', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100038', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100093', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100148', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099983', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099763', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099653', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099598', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100203', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099928', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099818', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099708', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1003 | Q34 | What are the names of the genes that are targeted by the drug Aclidinium Bromide in the treatment of emphysema? | In the context of emphysema, the drug Aclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%aclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%aclidinium bromide%" OR LOWER(syns_list) LIKE "%aclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857459', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857441', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857447', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857465', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857453', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.155 | Q34 | What are the names of the genes that are targeted by the drug Ciclesonide in the treatment of asthma? | In the context of asthma, the drug Ciclesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%ciclesonide%" OR LOWER(tradeNames_list) LIKE "%ciclesonide%" OR LOWER(syns_list) LIKE "%ciclesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217456', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217446', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217476', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217466', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1107 | Q34 | What are the names of the genes that are targeted by the drug Darolutamide in the treatment of prostate cancer? | In the context of prostate cancer, the drug Darolutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_list) LIKE "%darolutamide%" OR LOWER(syns_list) LIKE "%darolutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924405', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924414', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924419', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924421', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924428', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924433', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924435', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924440', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924412', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924398', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924391', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924386', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924426', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924407', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924400', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924393', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1704 | Q34 | What are the names of the genes that are targeted by the drug Histrelin Acetate in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Histrelin Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%histrelin acetate%" OR LOWER(tradeNames_list) LIKE "%histrelin acetate%" OR LOWER(syns_list) LIKE "%histrelin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097120', 'drugName': 'Histrelin Acetate', 'tradeNames_list': "['Supprelin', 'Supprelin la', 'Vantas']", 'syns_list': "['Histrelin acetate']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1980 | Q34 | What are the names of the genes that are targeted by the drug Selinexor in the treatment of diffuse large B-cell lymphoma? | In the context of diffuse large B-cell lymphoma, the drug Selinexor targets the gene exportin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diffuse large b-cell lymphoma%" OR LOWER(efo_term) LIKE "%diffuse large b-cell lymphoma%") AND (LOWER(drugName) LIKE "%selinexor%" OR LOWER(tradeNames_list) LIKE "%selinexor%" OR LOWER(syns_list) LIKE "%selinexor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193928', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194054', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194096', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194138', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194222', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194264', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194306', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194390', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194432', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194474', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194516', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194600', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194642', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194684', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194726', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194768', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194810', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194852', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194894', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194936', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194978', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195062', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195104', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195146', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195188', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195230', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195314', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195356', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195398', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195440', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195482', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195524', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195566', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195608', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195650', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195692', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195020', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194348', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194012', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193844', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193760', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193718', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195272', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194558', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194180', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193970', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193886', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193802', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.795 | Q34 | What are the names of the genes that are targeted by the drug Calcifediol in the treatment of parathyroid disease? | In the context of parathyroid disease, the drug Calcifediol targets the gene vitamin D receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parathyroid disease%" OR LOWER(efo_term) LIKE "%parathyroid disease%") AND (LOWER(drugName) LIKE "%calcifediol%" OR LOWER(tradeNames_list) LIKE "%calcifediol%" OR LOWER(syns_list) LIKE "%calcifediol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823427', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823451', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823459', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823467', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823483', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823491', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823499', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823515', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823523', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823531', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823507', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823411', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823395', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823387', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823443', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823475', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823435', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823419', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823403', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Diseases', 'efo_term': 'parathyroid disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.